Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by AIM ImmunoTech Inc.
< Previous
1
2
Next >
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer
November 14, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
November 09, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer
November 08, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
November 06, 2023
From
AIM ImmunoTech Inc.
Via
Business Wire
Tickers
AIM
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 30, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs
October 17, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
September 22, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative
September 11, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements
August 23, 2023
From
AIM ImmunoTech Inc.
Via
Business Wire
Tickers
AIM
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
August 15, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
August 09, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
August 08, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates
July 18, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
July 10, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series
July 05, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic
June 27, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research
June 27, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
June 14, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments
June 12, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update
May 15, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast
May 09, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)
April 12, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions
April 04, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
April 03, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise
March 30, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast
March 27, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease
March 16, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease
March 08, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
AIM ImmunoTech Issues Letter to Stockholders
March 06, 2023
From
AIM ImmunoTech Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.